NIGP 26904: Antihistamine Drugs

NIGP 26904 Antihistamine Drugs is an Item code that frames state and local pharmaceutical procurement activity, though the recent solicitations show this code captures a broader range of pharmaceutical and pharmacy services than the legacy description alone suggests. State and local governments soliciting under this code are pursuing naloxone and drug deactivation systems, on-site pharmacy services for employee health plans, tuberculosis housing services with integrated health support, and direct-to-manufacturer prescription programs. Issuing bodies include counties (Seminole County, Florida; Hall County, Georgia; Orange County, California), state health agencies (Texas Health and Human Services Commission; Utah Department of Health and Human Services), and county health departments. The work spans emergency pharmaceutical supplies, occupational health clinic pharmacy operations, vulnerable-population housing with healthcare coordination, and state-level pharmacy benefit innovation.

Recent activity concentrates in Florida, Georgia, California, Texas, and Utah. Representative solicitations include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Hall County, Georgia's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) for on-site pharmacy services at a county health clinic serving approximately 3,005 enrolled employees and dependents; the County of Orange, California's IFB 0803008401RE (posted April 21, 2026) for sodium hypochlorite and sulfuric acid supply to water treatment operations; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription contracting. Orange County's solicitation includes a five percent OCLSB and DVBE preference deduction, rising to eight percent if certified as both. Activity signals state and local focus on pharmaceutical supply chain efficiency, cost containment through direct contracting and on-site pharmacy models, and integration of pharmaceutical services into broader public health and housing initiatives.